v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenues $ 22,537,016 $ 37,037,108 $ 31,457,908
Cost of revenues (3,653,278) (4,383,363) (4,227,409)
Gross profit 18,883,738 32,653,745 27,230,499
Operating expenses:      
Selling and marketing expenses (10,264,507) (4,061,116) (2,547,000)
General and administrative expenses (14,119,024) (7,103,226) (8,546,880)
Research and development expenses (20,131,012) (6,174,365) (4,274,894)
Total operating expenses (44,514,543) (17,338,707) (15,368,774)
Income/(loss) from operations (25,630,805) 15,315,038 11,861,725
Interest expense, net (737,370) (576,359) (284,271)
Subsidy income 93,394 266 791,959
Other expenses, net (100,195) (651,657) (10,211)
Income/(loss) before income tax (26,374,976) 14,087,288 12,359,202
Income tax provision (1,166,148) (1,489,190) (1,701,019)
Net income/(loss) (27,541,124) 12,598,098 10,658,183
Less: Net Loss/(income) attributable to non-controlling interests 263,119 (144,729) (112,205)
Net income/(loss) attributable to Baird Medical Investment Holdings Limited's shareholders (27,278,005) 12,453,369 10,545,978
Other comprehensive loss      
Foreign currency translation adjustment 1,786,857 (1,135,939) (728,688)
Total comprehensive income/(loss) (25,754,267) 11,462,159 9,929,495
Less: Non-controlling interests 245,429 (144,729) (112,205)
Comprehensive income/(loss) attributable to Baird Medical Investment Holdings Limited's shareholders $ (25,508,838) $ 11,317,430 $ 9,817,290
Net income/(loss) per share, basic (in dollars per share) [1] $ (0.98) $ 0.57 $ 0.51
Net income/(loss) per share, diluted (in dollars per share) [1] $ (0.98) $ 0.57 $ 0.51
Weighted average number of shares - basic (in shares) [1] 27,792,704 21,826,549 20,588,236
Weighted average number of shares - diluted (in shares) [1] 27,792,704 21,826,549 20,588,236
Stock-based compensation expenses $ 17,500,000 $ 0 $ 0
General and administrative expenses      
Other comprehensive loss      
Stock-based compensation expenses 9,532,581    
Selling and marketing expenses      
Other comprehensive loss      
Stock-based compensation expenses $ 7,938,500    
[1] Shares related information for all periods retrospectively reflect the adjustments for Reverse Recapitalization (Note 3).